ReviewAmerican journal of stem cells2019
The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC.
Review in American journal of stem cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Modelling the impact of awareness campaigns on HPV transmission dynamics: a neural network-enhanced mathematical model.Scientific reports · 2026Article
- Article
- Cervical Cancer in the Era of HPV: Translating Molecular Mechanisms into Preventive Public Health Action.International journal of molecular sciences · 2025Review
- Visual inspection with acetic acid and colposcopy: screening of cervical cancer in resource-limited healthcare settings.Frontiers in global women's health · 2025Article
- Exploring the role of the oncology nurse in cervical cancer screening programs during times of transition.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2025Article
- Human Papillomavirus (HPV) Vaccination: Progress, Challenges, and Future Directions in Global Immunization Strategies.Vaccines · 2024Review
- Article
- Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
- Factors, associated with elevated concentration of soluble carbonic anhydrase IX in plasma of women with cervical dysplasia.Scientific reports · 2022Article
- Ethical Challenges to Improving Access to Human Papillomavirus Vaccines in Low- and Middle-Income Countries.NEJM evidence · 2022Article
- Article
- Assessment of Oral Human Papillomavirus Prevalence in Pediatric and Adult Patients within a Multi-Ethnic Clinic Population.Dentistry journal · 2022Article
- Visual appearance of the uterine cervix differs on the basis of HPV type status in high-grade squamous intraepithelial lesion: the results of a reliable method.BMC women's health · 2022Article
- Evaluation of human papillomavirus (HPV) genotyping assays using type-specific HPV L1 reference DNA.Genes & genomics · 2021Article
- Genotype Distribution Change After Human Papillomavirus Vaccination in Two Autonomous Communities in Spain.Frontiers in cellular and infection microbiology · 2021Article
- Review
- Aptima HPV Genotypes in Abnormal Cervical Samples in Different Age Groups - Implication on Vaccination Strategies.Journal of cytologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two of the leading strategies to prevent cervical cancer are prophylactic human papillomavirus (HPV) vaccination and routine Papanicolaou (Pap) testing. However, regardless of being vaccinated with first-generation (bivalent and quadrivalent) HPV vaccines at the recommended dosing schedule, many women are still found to have low- and high-grade cervical intraepithelial lesions. Studies have shown that this is largely due to: (1) first-generation vaccines only protecting against 70% of high-risk HPV types that cause cervical cancer (HPVs 16/18) and (2) vaccinated women being more prone to infection with non-protected high-risk HPV types than unvaccinated women. Fortunately, the FDA recently approved a nonavalent vaccine that protects against 5 additional high-risk HPV types that cause 20% of cervical cancers (HPVs 31/33/45/52/58), which is the only HPV vaccine currently available in the United States. Although the Advisory Committee on Immunization Practices (ACIP) recommends the nonavalent vaccine in men and women up to the age of 45 years, it does not recommend the nonavalent vaccine in those previously vaccinated with 3 doses of bivalent or quadrivalent vaccine, deeming them "adequately vaccinated". As this population is most at risk, this review serves to provide background and argue for a change in their recommendation.
Indexed as
Identifiers
31976155PMC6971474W3006288925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.